◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Rubicon Research Limited (RUBICON) Revenue 2025–2026

Name: Rubicon Research Limited (RUBICON) revenue history 2025-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Rubicon Research Limited annual revenue for fiscal 2026 was ₹17.3 billion, an increase of 36.6% from ₹12.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

RUBICON Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31
Total Revenue	₹17.3B	₹12.7B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RUBICON Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹5.3B	₹5.1B	₹4.8B	₹3.5B	₹3.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4503 Revenue — Astellas Pharma Inc.
4528 Revenue — Ono Pharmaceutical Co., Ltd.
4536 Revenue — Santen Pharmaceutical Co., Ltd.
GLAXO Revenue — GlaxoSmithKline Pharmaceuticals Limited
NOVN Revenue — Novartis AG

More RUBICON metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All RUBICON financial statements → Interactive RUBICON charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.